BURLINGTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and […]
Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ livesOverall […]
ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host DiseaseAbstract […]